CompletedNot Applicable

SGB Reduces the Incidence and Severity of CSA-AKI

China396 participantsStarted 2023-01-10

Plain-language summary

The incidence of acute kidney injury after cardiopulmonary bypass cardiac surgery is high, which increases postoperative mortality and is not conducive to the prognosis of patients. Stellate ganglion blocks increase renal blood flow, reduce inflammation and stress, and protect the heart muscle. In this study, stellate ganglion block was used to promote rapid recovery of kidney function after cardiopulmonary bypass cardiac surgery.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients of any gender were eligible provided they were between the ages of 18 and 80 years;
✓. American Society of Anesthesiologists (ASA) class of Ⅲ or IV.

Exclusion criteria

✕. emergency cardiac surgery；
✕. major vascular surgery；
✕. non-sinus rhythm, reoperation；
✕. contraindications for TEE or SGB；
✕. abnormal preoperative renal function；
✕. severe preoperative heart failure with left ventricular ejection fraction \< 30%, multi-organ dysfunction；
✕. and severe infection requiring continuous antibiotic treatment;
✕. enrolled in another clinical trial.

What they're measuring

The incidence and severity of CSA-AKI

Timeframe: From the end of surgey to postoperative day 7

Trial details

NCT IDNCT05652179

SponsorYangzhou University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-01

View on ClinicalTrials.gov More Stellate Ganglion Block trials